DBV Technologies | DBVT - Operating Profit

Stock Price
23.37
Daily Change
0.87 3.87%
Monthly
37.55%
Yearly
410.26%
Q1 Forecast
21.05

DBV Technologies reported $-34.28M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Acadia Pharmaceuticals USD 35.76M 3.38M Sep/2025
Alnylam Pharmaceuticals USD -29.96M 13.76M Sep/2025
Amarin USD -1.7M 8.47M Sep/2025
BioMarin Pharmaceutical USD -31.69M 308.58M Sep/2025
DBV Technologies USD -34.28M 6.83M Sep/2025
Halozyme Therapeutics USD 217.92M 15.48M Sep/2025
Incyte USD 431.31M 120.49M Sep/2025
Insmed USD -261.35M 7.48M Sep/2025
Ionis Pharmaceuticals USD -160.18M 300.02M Sep/2025
Neurocrine Biosciences USD 239.3M 93.7M Sep/2025
PTC Therapeutics USD 3.49M 38.35M Sep/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
Ultragenyx Pharmaceutical USD -170.89M 22.68M Sep/2025
United Therapeutics USD 389.3M 112.4M Sep/2025